Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Oct 5, 2017 -- Presentations emphasize potential role for plazomicin in treating bloodstream infections (BSI) due to carbapenem-resistant Enterobacteriaceae (CRE) as well as potential long-term clinical benefits for patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP) -- SOUTH SAN FRANCI...
Sep 28, 2017 Non-dilutive funding to support clinical development of antibacterial candidate for ESBL infections Company expects top-line Phase 1 results in 2017 and initiation of pivotal Phase 3 trial in 2018 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE...
Sep 27, 2017 SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced five upcoming presentations on plazomicin at the Infectious Diseases Society of A...
Sep 26, 2017 SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on September 20, 2017, the compensation committee of the Company's board of...
Sep 18, 2017 SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 2017 Cantor Fitzgerald Global Healthc...
Sep 18, 2017 SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Ms. Liz Bhatt as Chief Business Officer effective today. Ms. Bha...
Aug 21, 2017 SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on August 18, 2017, the compensation committee of the Company's board of dir...
Aug 8, 2017 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 2017 Wedbush PacGrow Healthcare Confer...
Aug 3, 2017 -- Plazomicin granted Breakthrough Therapy designation -- -- C-Scape Phase 1 study underway to evaluate orally-administered antibacterial candidate for infections due to ESBL-producing Enterobacteriaceae -- -- Conference call today at 4:30 p.m. Eastern Tim...
Jul 27, 2017 SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its second quarter financial results on Thurs...
Page:
1
... NextLast
= add release to Briefcase